ACW.ASX: ACW receives initial $5.5m R&D tax incentive rebate

ACW receives initial $5.5m R&D tax incentive rebate

Stock	Actinogen Medical Ltd (ACW.ASX)
Release Time	15 Oct 2025, 8:55 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Actinogen receives $5.5m R&D tax rebate, with $1.9m more pending

Key Points

Actinogen receives $5.5m R&D tax incentive rebate from ATO
Further $1.9m rebate pending approval of Advanced Overseas Finding
Rebates to fund Alzheimer's phase 2b/3 clinical trial milestones

Full Summary

Actinogen Medical has received a research and development tax incentive (RDTI) rebate of $5,489,600 from the Australian Tax Office (ATO) for the 2025 financial year. The company is also awaiting review and approval from the ATO for a further RDTI rebate of $1,874,143 relating to an Advanced Overseas Finding application, which will take the total 2025 RDTI rebate to $7,363,743. The RDTI is an important part of Actinogen's ongoing sources of funds as it rapidly approaches key milestones in its Alzheimer's phase 2b/3 clinical trial, with an interim analysis in January 2026 and final results anticipated in Q4 2026. Actinogen entered into a loan agreement with Endpoints Capital for $3.0m as an advance against its FY25 RDTI, which has now been repaid from the $5,489,600 received, with net proceeds of $2,342,027 received by the company.

Guidance

Actinogen is rapidly approaching key milestones in its Alzheimer's phase 2b/3 clinical trial, with an interim analysis in January 2026 and final results anticipated in Q4 2026.